Key Highlights
- Stephan Schann promoted to Chief Scientific Officer at Domain Therapeutics, leading GPCR-targeted cancer immunotherapy development.
- Domain to advance novel drug candidates, including DT-7012 and DT-9045, under Schann’s leadership.
- Schann brings over two decades of biopharmaceutical leadership experience, furthering Domain’s innovative R&D in immuno-oncology.
Source: Business Wire
Notable Quotes
- “His visionary leadership, scientific acumen, knowledge of Domain and unwavering dedication to our shared mission make him ideal to lead our remarkable research team as we strive to progress our pipeline of first-in-class and best-in-class GPCR targeted cancer immunotherapies to deliver effective treatments to patients.” – Dr. Tony Johnson, President and CEO at Domain Therapeutics
- “I look forward to continuing to support the Company and to further developing Domain’s unique precision research approach, translating our groundbreaking science into meaningful, differentiated and life-saving treatments for cancer patients.” – Stephan Schann, CSO at Domain Therapeutics
SoHC's Take
The appointment of Stephan Schann as Chief Scientific Officer marks a significant milestone for Domain Therapeutics in its pursuit of pioneering GPCR-targeted cancer immunotherapies. Schann’s extensive experience and deep understanding of the biopharmaceutical landscape, combined with his proven track record within Domain, position him uniquely to lead the company’s scientific strategy forward. This strategic leadership transition underscores Domain’s commitment to innovation and excellence in the development of novel cancer treatments. As the company progresses its promising pipeline, the industry watches closely, anticipating the impact of these advancements on the future of cancer therapy.
